Daily skin variation caused substantial target underdose in kidney proton SABR
Daily surface changes shifted proton beam depth by up to 17.4 mm and reduced accumulated target D99 by up to 24.3%.
Daily surface changes shifted proton beam depth by up to 17.4 mm and reduced accumulated target D99 by up to 24.3%.
Combining ISUP grade with 3–6-month PSA-density kinetics separated seven-year biochemical control at 93.5% versus 53.4% after SABR without ADT.
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
In 2024, only 3.2% of English patients began curative radiotherapy within the 49-day target despite rapidly rising demand.
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Two- to five-millimetre gastrointestinal margins usually limited delivered dose increases but frequently failed to encompass interfraction organ motion.
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.
In free-breathing lung stereotactic ablative radiotherapy, posterior drift exceeded the 4-millimetre margin in 15.7% of patients within 20 minutes.
Three of four patients completed final imaging and lung stereotactic ablative radiotherapy within one assisted breath-hold, with only grade 1 adverse events.
K-means matched hybrid optimization for margin volume while reducing median computation time from 306.9 seconds to 0.19 seconds.